Tsushima Kenji, Kubo Keishi, Koizumi Tomonobu, Yamamoto Hiroshi, Fujimoto Keisaku, Hora Kazuhiko, Kan-Nou Yutaka
First Department of Internal Medicine, Shinshu University School of Medicine, Asahi, Matsumoto, Japan.
J Clin Apher. 2002;17(2):97-102. doi: 10.1002/jca.10019.
Acute respiratory distress syndrome (ARDS) is characterized by a high mortality rate. We have studied whether direct hemoperfusion using a polymyxin B immobilized fiber column (PMX-DHP) is effective for acute lung injury (ALI) and ARDS. Two ALI and eighteen ARDS patients were evaluated, four congestive heart failure (CHF) patients were evaluated as cardiogenic pulmonary edema, and we retrospectively compared the outcome with ten patients with ARDS who had been hospitalized between 1990 and 1998 as the untreated group. PMX-DHP was carried out twice at a rate of 80-100 ml/minute for 2 hours, with a time interval of approximately 24 hours. We monitored systolic blood pressure (BP), diastolic BP, and the PaO(2)/FIO(2) (PF) ratio before and after PMX-DHP treatment. The mortality was classified if patients were alive at day 30 after initiating PMX-DHP. The mortality of ARDS patients was approximately 20%. Systolic BP increased significantly from 106 +/- 20 to 135 +/- 21 and to 125 +/- 20 mmHg on the following day. Diastolic BP increased from 61 +/- 16 to 78 +/- 15, and to 72 +/- 12 mmHg. The PF ratio increased significantly from 125 +/- 54 to 153 +/- 73, and 163 +/- 78 Torr. CHF patients did not reveal improvement of systolic, diastolic BP, and PF ratio after PMX-DHP. Eight of ten patients in the untreated group died through exacerbated ARDS. In ARDS patients, PMX-DHP improved circulatory disturbance and oxygenation despite the underlying diseases. The mortality improved compared with that before induction of PMX-DHP.
急性呼吸窘迫综合征(ARDS)的特点是死亡率高。我们研究了使用多粘菌素B固定化纤维柱(PMX-DHP)进行直接血液灌流对急性肺损伤(ALI)和ARDS是否有效。评估了2例ALI患者和18例ARDS患者,4例充血性心力衰竭(CHF)患者被评估为心源性肺水肿,并且我们回顾性地将结果与1990年至1998年期间住院的10例未接受治疗的ARDS患者作为未治疗组进行了比较。以80-100毫升/分钟的速率进行PMX-DHP两次,每次2小时,时间间隔约24小时。我们监测了PMX-DHP治疗前后的收缩压(BP)、舒张压和动脉血氧分压/吸入氧分数(PF)比值。如果患者在开始PMX-DHP治疗后30天存活,则对死亡率进行分类。ARDS患者的死亡率约为20%。收缩压从106±20显著升高至135±21,并在次日升至125±20 mmHg。舒张压从61±16升高至78±15,并在次日升至72±12 mmHg。PF比值从125±54显著升高至153±73,并在次日升至163±78 Torr。CHF患者在PMX-DHP治疗后未显示收缩压、舒张压和PF比值的改善。未治疗组的10例患者中有8例因ARDS加重而死亡。在ARDS患者中,尽管存在基础疾病,PMX-DHP仍改善了循环障碍和氧合。与诱导PMX-DHP之前相比,死亡率有所改善。